HUMAN MONOCLONAL ANTIBODY OR ANTIGEN LINKING PART OF THE SAME WHICH SPECIFICALLY CONNECTS WITH HUMAN CD40 AND THE ACTIVE, ISOLATED HYBRIDOMA CELL LINEAGE, PHARMACEUTICAL COMPOSITION UNDERSTANDING THE SAME MOSABLE FABRICATION ANTIGEN CONNECTION PORTION
AMGEN FREMONT INC.;Abgenix, INC.;PFIZER PRODUCTS INC.
发明人:
Jose Corvalan,Ronald P. Gladue,Vahe Bedian,Xiao Feng,Xiao-Chi Jia
申请号：
BRPI0214137
公开号：
BRPI0214137B1
申请日:
2002.11.08
申请国别(地区):
BR
年份:
2019
代理人:
摘要：
"antibodies to cd40, pharmaceutical composition comprising them, use thereof in the manufacture of a medicament, isolated cell line, isolated nucleic acid molecule, vector comprising the same, host cell and method of manufacturing said antibodies". The present invention relates to antibodies and antigen binding moieties thereof which specifically bind to cd40, preferably human cd40, and function as cd40 agonists. The invention also relates to human anti-cd40 antibodies and antigen binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or fusion protein portions. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-cd40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of manufacturing human anti-cd40 antibodies, compositions comprising such antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides methods of gene therapy using nucleic acid molecules encoding heavy and / or light chain immunoglobulin molecules comprising human anti-cd40 antibodies. The invention also relates to transgenic animals comprising the nucleic acid molecules of the present invention."anticorpos para o cd40, composição farmacêutica compreendendo os mesmos, uso dos mesmos na fabricação de um medicamento, linhagem de célula isolada, molécula de ácido nucléico isolada, vetor compreendendo a mesma, célula hospedeira e método de fabricação dos referidos anticorpos". a presente invenção refere-se a anticorpos e porções de ligação a antígeno dos mesmos que se ligam especificamente ao cd40, de preferência cd40 humano e que funcionam como agonistas do cd40. a invenção também refere-se a anticorpos anti-cd40 humanos e porções de ligação a antígeno dos mesmos. a invenção também refere-se a anticorpos que são quiméricos, biespecíficos, derivatizados, an
